Open AccessRandomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
Author(s) -
Prasad Apsangikar,
Pravin Ghadge,
Manoj Naik,
Santosh Nair,
Ravikiran Payghan
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s307746
Subject(s) - medicine , macular degeneration , ranibizumab , visual acuity , ophthalmology , clinical endpoint , biosimilar , clinical trial , adverse effect , immunogenicity , surgery , bevacizumab , immune system , chemotherapy , immunology
The study was undertaken for regulatory purposes to establish clinical biosimilarity and interchangeability of a ranibizumab biosimilar with reference product.